SUMMARY Vigabatrin (y-vinyl GABA) is a new anticonvulsive drug that irreversibly inhibits the activity ofGABA transaminase. The effect ofvigabatrin on neurotransmission-related amino acids in CSF of 28 epileptic patients was studied and the relationship between the amino acid pattern and clinical response during 7 months of administration ofvigabatrin. Of this study population, 46% had more than 50% decrease in seizure frequency (responders). In 54% the seizures decreased less than 50% (nonresponders). In the whole study group, the levels of total GABA during vigabatrin treatment were 283%, free GABA 197%, homocarnosine 310% and glycine 128% that ofthe levels at baseline in the same patients. Glutamate, glutamine, aspartate, asparagine, and taurine concentrations did not change. The amino acid pattern in CSF during administration of vigabatrin did not differ significantly in responders and nonresponders. The study suggests that both GABAergic and glycinergic neurotransmission are affected by vigabatrin. The changes in CSF levels of neurotransmitter amino acids are, however, not necessarily related to the clinical response.
Vigabatrin (y-vinyl GABA, 5-amino-4-hex-enoic acid), is an anticonvulsive drug that inhibits GABA transaminase (GABA-T, EC 2.6.1.19) activity by an irreversible mechanism.' Levels of GABA and homocarnosine (HC) in the brain and cerebrospinal fluid (CSF) of animals as well as CSF levels of GABA and HC in humans are elevated up to 2-4 fold during vigabatrin administration at doses that have anticonvulsive efficacy. '2 Previous data about the unchanged levels of markers of cholinergic, dopaminergic, serotonergic and peptidergic systems3 4 and the relatively few side effects observed in patients during vigabatrin administration suggest that the mechanism of action is quite specifip. However, the elevation of GABA levels alone seems not to explain all the effects ofvigabatrin. First, studies of the rat brain suggest that other amino acids, such as fi-alanine and hypotaurine, are also affected by vigabatrin.5 Second, the maximal elevations of GABA levels in the brain and CSF are not always correlated with maximal anticonvulsive efficacy.6 Third, elevation of CSF levels of GABA seems to be a constant finding in patients receiving vigabatrin, but the anticonvulsive effect is found only in 40-60% of these different types ofseizures both in animals and humans, and previous studies have proposed different anatomical and biochemical backgrounds for different types of seizures. This suggests that other transmitter systems than GABA are also involved in seizure regulation.>" Finally, the metabolic connections between GABA and other amino acids (especially glutamate) suggest that chronic elevation of GABA in the brain could induce secondary changes in other amino acids.
In the present study we determine the levels of excitatory (glutamate (Glu), aspartate (Asp)) and inhibitory (GABA, taurine (Tau), glycine (Gly)) amino acids and three amino acids related to them metabolically (glutamine (Gln), asparagine (Asn), homocarnosine (HG)) in CSF of epileptic patients receiving different doses of vigabatrin. The overall effect of vigabatrin on the amino acid pattern was evaluated as well as the relationship between changes in amino acid levels and clinical response.
Patent and methods

Patients
Twenty eight patients with drug-refractory epilepsy were included in the study. Each (2) number ofseizures reduced by less than 50% with GI (Group B). Patients with less than 50% reduction in seizures without GI (Group C) were excluded from the study after the dosemodification phase. In further data analysis Groups B and C were called nonresponders.
Collection ofCSF
After the Ethics Committee of Vaajasalo Epilepsy Hospital had given its approval and the patients had given their oral consent, lumbar samples of CSF were collected. Patients had been immobile and had fasted overnight (0800-1000 h) before the sample was taken. CSF samples were divided into aliquots immediately and frozen in liquid nitrogen. They were then stored at -70°C until analysed. Amino acids were measured from the pool of CSF containing the 5-10th ml of CSF. Samples taken from the same patient before and during vigabatrin therapy were analysed at the same time. Only one sample was taken from each control. From the epileptic patients the first sample was collected before the administraPitkdnen, Matilainen, Ruutiainen, Lehtinen, Riekkinen tion of vigabatrin. The second sample was taken after 7 months of therapy with vigabatrin or if vigabatrin had to be stopped due to a poor response after the dose-modification phase.
Amino acid analysis The levels of Glu, Gln, Asp, Asn, total GABA (TGABA), free GABA (FGABA), homocarnosine (HC), Tau, Gly, and vigabatrin were analysed by high performance liquid chromatography as described previously.3
Statistical analysis
The statistical analyses were performed at Kuopio University Computer Center by SPSS-programs. The statistical significance of parameters from the same patients at different times (two time points) was evaluated by Wilcoxon's test for matched samples. Differences between the controls and patients with epilepsy or between other groups were evaluated by Mann-Whitney U-test. The correlation between the different parameters was evaluated by Spearman's correlation test.
Results
Ofthe study population, 13 (46%) had more than 50% (p < 0001) decrease in seizure frequency (responders). In 15 (54%) of the patients the seizures decreased, but by less than 50% (p < 0-01) (nonresponders); and for five of this patient group vigabatrin was stopped after the 3 month dosemodification phase due to the poor anticonvulsive response (Group C). Ten of the nonresponders showed global improvement during vigabatrin therapy (social activity, improved communication, daily activities) (Group B) and continued to the long-term phase. In this group a slight decrease in seizure-frequency was also observed (to 73%, p < 0-01).
In the whole study group the seizure frequency decreased to 50 2% (p < 0 001) at the time of the second lumbar puncture, as compared with baseline (table 1) . Especially were the partial types of seizures suppressed (to 46-9%, p < 0.001). The number of primary generalised seizures also decreased, but the difference was not significant (to 55%, n = 4, p = 0 0679). The vigabatrin doses and levels in CSF are shown in table 2. Vigabatrn did not affect the plasma levels of other anticonvulsive medication.
In the whole patient group the administration of vigabatrin elevated (see fig) the CSF levels of TGABA by 283% (p < 0'001, range 170-470%), FGABA by 197% (p < 0'001, range 117-386%), and HC by 310% (p < 0*001, range 199-586%) compared with the levels at baseline in all patients. The mean elevation of Gly was 128% (p < 0 001, range 84-175%) of that at baseline. Glycine levels were elevated in all except two patients. Glu, Gln, Asp, Asn, and Tau levels were unchanged during vigabatrin administration. The The elevations in TGABA (266% for responders and 298% for nonresponders of the levels at baseline), FGABA (233% and 180% respectively), HC (309% and 301%, respectively), and Gly (122% and 110%, respectively) were observed in both responders and nonresponders (table 3) . At baseline the nonresponders had slightly lower levels ofTGABA and HC than the responders did. During vigabatrin therapy the Tau levels were lower (69%) in nonresponders than in responders. In the nonresponders Tau levels were also lower than in controls both before and during vigabatrin administration. Gly levels were also slightly lower (76%) in nonresponders than in responders during vigabatrin therapy. Their baseline levels of Gly were also lower (88%) than in the controls. The FR % (seizure frequency during vigabatrin administration per seizure frequency at baseline) correlated with Tau (r = -0-6379, n = 21, p < 0-05) levels in samples taken during vigabatrin treatment.
The CSF levels of vigabatrin and amino acids were about the same whether taken after 3 months or 7 months of vigabatrin administration. No difference in amino acid levels of CSF was observed between patients with partial type epilepsy and those with primary generalised seizures at baseline or during vigabatrin therapy.
The doses of vigabatrin (expressed either g/day or mg/kg/day) and the CSF levels of vigabatrin did not differ between responders and nonresponders. Vigabatrin dose (mg/kg/day) correlated slightly with the CSF levels of vigabatrin (r = 0-5909, n = 21, p < 0-01).
Discussion
The present study shows that administration of vigabatrin to epileptic patients affects GABAergic neurotransmission especially, but levels of glycine in CSF are also elevated. Furthermore, patients with good clinical response to vigabatrin had, for the most part, a pattern of amino acids in CSF similar to that in patients with poor response.
Most of the patients in the study had drugrefractory seizures of partial onset. Previous neuropathological,'3 neurophysiological,'4 and neuroradiological'3 studies suggest that in such patients the limbic areas are affected most. Lloyd, et al '5 reported that 50-60% of the drug-refractory patients with partial epilepsy who were treated surgically had defects in GABAergic transmission. Such findings have not been confirmed in all studies.'617 Nor in the present study did we observe lowered GABA levels in CSF of epileptic patients. In the same group of patients, however, administration of vigabatrin resulted in a more than 50% decrease in seizure number in 47% of the patients with partial epilepsy and a concomitant 2-5-fold elevation of CSF levels of TGABA, which also reflects the elevation of brain GABA levels.'8 '9 In the rest of the patients with partial epilepsy, however, the CSF levels of GABAergic GABA in neurons of the substantia nigra pars reticulata is important for the depression of seizure progression in animals after vigabatrin administration. The most critical areas for the antiepileptic effect of vigabatrin may not overlap with the anatomical substrates of different types of seizures, which may partly explain why some patients respond to vigabatrin and others continue to have frequent seizures despite elevated levels of GABA. In conclusion, potentiation of GABAergic neurotransmission alone is not sufficient to prevent seizures; but other factors are involved in seizure control, at least in some patients.
Vigabatrin inhibits GABA-T in both cortical and subcortical structures as well as in neuronal and glial compartments.'0 Chronic elevation of GABA in widespread structures of the brain seems to have relatively few side effects and little effect on the EEG,'2 which suggests few interactions with other neurotransmitters or neuromodulators, as was reported previously.34
However, we observed that during vigabatrin administration the levels of Gly, which is an inhibitory transmitter, are elevated in CSF by about 20% in almost all patients. This disagrees with previous animal studies, where the brain levels of glycine remained unchanged. The spinal cord obviously contributes significantly more to the CSF levels of Gly than does the brain tissue, which may partly explain the differences in brain and CSF data. Glycine elevation was poorly correlated with the clinical response. In addition, both the mechanism of elevation and the role of glycine in the anticonvulsive action of vigabatrin are unknown.
The neuronal tracts containing Glu and Asp seem to modulate effectively both the spread and neuropathological consequences of seizures in animals.2' In human epileptic foci Glu and Asp levels have been reported to be lowered. On the other hand, the plasma levels of Glu in patients with spike-and-wave epilepsy are elevated. 25 We found lowered levels of these excitatory transmitters in the CSF of epileptic patients. Neither vigabatrin nor chronically elevated levels of GABA in the brain seemed to affect these amino acids. The metabolites, Gln and Asn, as well as Tau were also unchanged during vigabatrin therapy, which agrees with previous animal data. 26 Baseline levels of amino acids in CSF of epileptic patients did not reveal any defect in GABAergic transmission or enhancement of excitatory transmission in epileptic patients compared with controls, as far as the CSF levels of amino acids reflect their functional state in the brain. The clinical response to vigabatrin could not be predicted on the basis of baseline values of amino acids, because the amino acid pattern of responders and nonresponders differed only in cases of TGABA and HC, which later during vigabatrin therapy were equally elevated in the two groups. This finding also suggests that the GABAergic system in general can respond as effectively in nonresponders as in responders. No conclusions about anatomical and subcellular differences in GABA elevation between the two groups can be made on the basis of CSF data.
The present study suggests only a weak dose-dependency between vigabatrin dose and elevation of vigabatrin or amino acid levels in CSF or clinical response. The small number ofpatients included in the study as well as the narrow dose-range may have affected the results. Such correlations have been reported previously by Ben-Menachem, et al. 27 In conclusion, both GABAergic and glycinergic transmissions are affected during vigabatrin administration in humans. Evidently the CSF levels of neurotransmission-related amino acids evaluated before or during vigabatrin adminstration are not necessarily related to the clinical response of vigabatrin. The present findings show, however, that enhancement of inhibitory neurotransmission in the central nervous system by vigabatrin has anticonvulsive efficacy in nearly half of the epileptic patients who had previously been drug-refractory.
